Zydus Cadila has received approval from the US FDA to market zonisamide capsules in different strengths of 25 mg, 50 mg and 100 mg. The drug falls in the anti-epileptic segment.
The branded sales of zonisamide capsules in the US market was estimated at USD 178 million in 2005 as per IMS. The company will market the drug through its US subsidiary Zydus Pharmaceuticals (USA) Inc., a company release stated.
According to the release, the group has received 17 ANDA approval since the commencement of filing process in FY 2003-04. So far, the group has filed 41 ANDAs and 45 DMFs.